EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Modern Directions in Early Biomarker Diagnostics of Parkinson's Disease

Aliaksandr Kryshtofik, Julia Grygorowicz, Gabriela Faria, Monika Sas-Wyżykowska, Alina Mykhalevych, Michał Niedziela, Monika Maruszak, Anna Wyżykowska, Aleksandra Blachucik, Akhil Roy Subramoney

Quality in Sport · 14.07.2026 · 63 · 73169

DOI: 10.12775/qs.2026.63.73169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 14.07.2026. Verfasst von Aliaksandr Kryshtofik und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson’s disease (PD) is the fastest-growing neurological disorder globally. Traditional diagnosis, which relies on motor symptoms, is associated with a 15–24% error rate and occurs after significant loss of dopaminergic neurons. Early biomarker identification is essential for biological redefinition of PD and timely intervention.

Objective

To synthesize evidence from the past five years on minimally invasive biomarkers and assess whether multimodal panels offer greater diagnostic precision than single tests.

Methods

A systematic review of PubMed and Scopus (January 2021–January 2026) was conducted per PRISMA guidelines, including meta-analyses and original studies on α-synuclein seed amplification assays (SAA), neuronally derived extracellular vesicles (LIEVs), neurofilament light chain (NfL), and advanced imaging (OCT-A, MRI).

Results

SAA exhibited 96% sensitivity in GBA1 mutation carriers and 98.6% in hyposmic individuals with dopaminergic deficits, but only 67.5% in LRRK2 carriers. Serum LIEV-associated α-synuclein distinguished prodromal cases with high precision (AUC=0.91). NfL predicted functional decline (OR=2.54) up to five years before diagnosis. Advanced neuroimaging and skin RT-QuIC tests showed diagnostic accuracies from 82% to 100%.

Conclusion

PD diagnosis is shifting from clinical observation to biological profiling. Multimodal biomarker panels integrating molecular, microvascular, and imaging data provide the most precise risk stratification, enabling timely, targeted neuroprotective interventions by rehabilitation specialists.

Zitieren

APA

Kryshtofik, A., Grygorowicz, J., Faria, G., Sas-Wyżykowska, M., Mykhalevych, A., Niedziela, M., Maruszak, M., Wyżykowska, A., Blachucik, A., & Subramoney, A. R. (2026). Modern Directions in Early Biomarker Diagnostics of Parkinson's Disease. Quality in Sport, 63, 73169. https://doi.org/10.12775/qs.2026.63.73169

Vancouver

Kryshtofik A, Grygorowicz J, Faria G, Sas-Wyżykowska M, Mykhalevych A, Niedziela M, et al. Modern Directions in Early Biomarker Diagnostics of Parkinson's Disease. Quality in Sport. 2026;63:73169. doi:10.12775/qs.2026.63.73169

BibTeX
@article{Kryshtofik2026,
  author = {Kryshtofik, Aliaksandr and Grygorowicz, Julia and Faria, Gabriela and Sas-Wyżykowska, Monika and Mykhalevych, Alina and Niedziela, Michał and Maruszak, Monika and Wyżykowska, Anna and Blachucik, Aleksandra and Subramoney, Akhil Roy},
  title = {Modern Directions in Early Biomarker Diagnostics of Parkinson's Disease},
  journal = {Quality in Sport},
  year = {2026},
  volume = {63},
  pages = {73169},
  doi = {10.12775/qs.2026.63.73169}
}
Kostenlos starten →